UK markets closed

Aileron Therapeutics, Inc. (ALRN)

NasdaqCM - NasdaqCM Delayed price. Currency in USD
Add to watchlist
6.63-0.46 (-6.49%)
At close: 04:00PM EDT
6.40 -0.23 (-3.47%)
After hours: 06:43PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 32.39M
Enterprise value 11.18M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)2.89
Enterprise value/revenue N/A
Enterprise value/EBITDA -0.88

Trading information

Stock price history

Beta (5Y monthly) 2.18
52-week change 3434.68%
S&P500 52-week change 327.86%
52-week high 37.12
52-week low 31.01
50-day moving average 35.05
200-day moving average 32.72

Share statistics

Avg vol (3-month) 338.87k
Avg vol (10-day) 343.48k
Shares outstanding 54.89M
Implied shares outstanding 64.89M
Float 83.73M
% held by insiders 10.70%
% held by institutions 163.24%
Shares short (15 Mar 2024) 432.95k
Short ratio (15 Mar 2024) 41.53
Short % of float (15 Mar 2024) 40.85%
Short % of shares outstanding (15 Mar 2024) 40.67%
Shares short (prior month 15 Feb 2024) 431.2k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:20
Last split date 311 Nov 2022

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2022
Most-recent quarter (mrq)30 Sept 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-39.79%
Return on equity (ttm)-76.36%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -12.64M
Net income avi to common (ttm)-12.94M
Diluted EPS (ttm)-2.85
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)12.07M
Total cash per share (mrq)2.66
Total debt (mrq)N/A
Total debt/equity (mrq)N/A
Current ratio (mrq)7.88
Book value per share (mrq)2.47

Cash flow statement

Operating cash flow (ttm)-13.83M
Levered free cash flow (ttm)-8.51M